Brief: Alzinova: Drug Substance For ALZ-101 Vaccine Meets Requirements Of Upcoming Clinical Phase 1B Study

Alzinova AB

08/01/2021 07:03

Jan 8 (Reuters) - Alzinova AB  ALZ.ST :
    * DRUG SUBSTANCE FOR THE ALZ-101 VACCINE IS NOW PRODUCED -
MEETS
THE REQUIREMENTS OF THE UPCOMING CLINICAL PHASE 1B STUDY
    * CLINICAL TRIAL WITH ALZ-101 ON ALZHEIMER'S DISEASE
PATIENTS IS
EXPECTED TO START DURING Q2 OF 2021.

Source text for Eikon:  ID:nWkr34gvHx 
Further company coverage:  ALZ.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))